News

Ebglyss is now approved for children and adults aged 12 years and older.

In case you missed it, this week we had news about adverse event profiles among pediatric patients treated with JAK inhibitors, positive results from a phase 3 trial of dupilumab for chronic spontaneous urticaria, and the impact of tropical weather on patients with atopic dermatitis.

Armstrong shared insights on the recently released NPF psoriasis health indicator report including pearls on national health data and unmet needs in public health campaigns.

Misleading marketing and incomplete scientific data have led to widespread misinformation about botulinum toxin products.

Researchers authored a manuscript detailing considerations for GPP diagnosis, definitions, and management.

Precision measurements are necessary to improve the current therapeutic armamentarium in pigmentary disorders.

Researchers reported several factors and indicators that may predict early-stage systemic sclerosis among patients in Japan.

The subsequent MAD portion of the study has commenced dosing. Results are anticipated in Q4.

Hurricane flooding results in a surge of mold, mildew, and allergens, which can trigger or exacerbate AD symptoms.

The trial showcased the continued efficacy of apremilast, with 2-year data on the forefront.

A recent reviewed showed that self-stigma in patients with skin disease is influenced by body image issues and social support.

Shanna Miranti, MMS, PA-C, reviews 2 patient cases of pseudo acne fulminans, offering perspectives on treatment and management strategies.

Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between October and December. Share your thoughts with us by September 25.

New study results show promise in dupilumab for bullous pemphigoid, with 59% of patients avoiding disease relapse.

These positive data will support US regulatory submission by end of 2024.

Swiss researchers found significant gender differences in melanoma care, including variations in information preferences and treatment decision-making.

The review assessed infections, gastrointestinal AEs, blood and lymphatic disorders, and nervous system and musculoskeletal/connective tissue disorders.

Researchers stated the lack of reported clinical validation data raises concerns about their effectiveness and safety.

A recent review found glycyrrhizin improves minoxidil's efficacy in treating AA, showing reduced severity and improved hair density.

Researchers reported that second-year students were more likely to identify dermatological conditions, particularly in White patients.

It is important that dermatology providers can easily recognize and treat communicable sports dermatoses, writes Shanna Miranti, MMS, PA-C.

The study reported that UST leads in dose escalation frequency, but also had lower discontinuation rates when compared to ADA and ETN.

A recent review found the LDI shows significant symptom improvement, but needs further study for long-term maintenance.

Dermatology Times spoke with Leah Howard, JD, of the NPF, and Trisha, the mother of a young girl with psoriasis, to discuss Otezla's implications in the therapeutic landscape.

The oral TYK2 inhibitor demonstrated biologic-level efficacy.

Keep up with the latest headlines in dermatology from the past week, including research into "zombie cells" in skin disorders, tartrazine's effects on skin transparency, and more.

In case you missed it, this week we had news about phase 2 initiation of EVO756 for chronic inducible urticaria, IBI363's Fast Track Designation for advanced melanoma, Arcutis' enrollment of the last patient in ARQ-255 trial for alopecia areata, and more.

A recent study investigated the acceptability, barriers, and facilitators associated with digital health tools.

The JAK1 inhibitor provided significant relief for 2 patients with refractory PN.